All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center, Tampa, US. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Shah shares data from the 2-year follow-up of the ZUMA-3 trial, discussing the long-term impact of allogeneic stem cell transplants. Shah outlines promising findings on overall survival for different patient groups and highlights a lack of trend in toxicity data.
Two-year follow-up of KTE-X19 in adult patients with R/R B-ALL: ZUMA-3 trial
The updated findings from the ZUMA-3 trial demonstrate that with longer follow-up and a larger pooled data set, outcomes remained stable over time in adult patients with R/R...
Brexucabtagene autoleucel approved by the FDA for use in adult ALL
On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be approved by the U.S. Food and Drug Administration (FDA)...
Subscribe to get the best content related to ALL delivered to your inbox